Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 660 results for position

  1. For a short explanation of why the committee made this recommendation for research, see the rationale section on position of the baby during cord clamping .

    committee made this recommendation for research, see the rationale section on position of the baby during cord clamping . Any...

  2. The EOS 2D/3D imaging system (DG1)

    Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton

  3. Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

    Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.

  4. Repositioning:- When repositioning a person who is at risk of developing a pressure ulcer, what is the most effective position – and optimum frequency of repositioning – to prevent a pressure ulcer developing?

    who is at risk of developing a pressure ulcer, what is the most effective position – and optimum frequency of repositioning – to prevent...

  5. Child maltreatment: when to suspect maltreatment in under 18s (CG89)

    This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help health professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.

  6. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.

  7. Fetal monitoring in labour (NG229)

    This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.

  8. Upadacitinib for treating severe rheumatoid arthritis (TA665)

    Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.

  9. Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) (DG47)

    NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care. We will review this decision if a stakeholder notifies NICE again of the topic

    Sections for DG47

  10. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

  11. Upadacitinib for treating moderate rheumatoid arthritis (TA744)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.

  12. Spinal injury: assessment and initial management (NG41)

    This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It covers traumatic injuries to the spine but does not cover spinal injury caused by a disease. It aims to reduce death and disability by improving the quality of emergency and urgent care.

  13. Antenatal care (NG201)

    This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support. We have also published a guideline on postnatal care , which covers the topics of emotional attachment and baby feeding.

  14. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.

  15. Statement on engagement with tobacco industry organisations

    Position statement The UK Government is a signatory and party to the WHO Framework Convention on Tobacco Control (FCTC). As an Arm's...